Clinical Trial

Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 27, 2025 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aimed to evaluate the efficacy and safety of Mavacamten compared to no treatment in patients with symptomatic latent obstructive hypertrophic cardiomyopathy. The trial was randomized into two groups: Mavacamten group and Non-Mavacamten group. Over the 30-week treatment period, patients underwent a series of assessments at predefined time points, including transthoracic echocardiography, electrocardiogram (ECG), Holter monitoring, NYHA functional classification, Kansas City Cardiomyopathy Questionnaire (KCCQ), and cardiac biomarkers.
Trial Details
NCT Number NCT06947590
Lead Sponsor Xu Liu
Conditions HCM - Hypertrophic Cardiomyopathy, Mavacamten
Enrollment 78 participants
Start Date 2025-04-20
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-27